HMOX1 and melanoma: In BRAFV600E MeOV-1 melanoma cells, vemurafenib, a BRAFV600E inhibitor, showed limited efficacy because the expression of BACH1 was reduced, and HO-1 (encoded by HOMX1) was subsequently upregulated.